BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 25077370)

  • 21. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade.
    Mommers EC; Leonhart AM; Falix F; Michalides R; Meijer CJ; Baak JP; Diest PJ
    J Pathol; 2001 Jul; 194(3):327-33. PubMed ID: 11439365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma.
    Lucarelli AP; Martins MM; Montor W; Oliveira V; Galvão MA; Piato S
    Sao Paulo Med J; 2011 Dec; 129(6):371-9. PubMed ID: 22249792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
    Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
    Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
    Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
    Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall survival is improved when DCIS accompanies invasive breast cancer.
    Kole AJ; Park HS; Johnson SB; Kelly JR; Moran MS; Patel AA
    Sci Rep; 2019 Jul; 9(1):9934. PubMed ID: 31289308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pure ductal carcinoma in situ and in situ component of ductal invasive carcinoma of the breast. A preliminary morphometric study.
    Giardina C; Serio G; Lepore G; Lettini T; Dalena AM; Pennella A; D'Eredità G; Valente T; Ricco R
    J Exp Clin Cancer Res; 2003 Jun; 22(2):279-88. PubMed ID: 12866579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
    Mack L; Kerkvliet N; Doig G; O'Malley FP
    Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
    Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
    J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer.
    Zhang W; Gao EL; Zhou YL; Zhai Q; Zou ZY; Guo GL; Chen GR; Zheng HM; Huang GL; Zhang XH
    World J Surg Oncol; 2012 Dec; 10():262. PubMed ID: 23216911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
    Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer.
    Cedolini C; Bertozzi S; Londero AP; Seriau L; Andretta M; Agakiza D; Fongione S; Uzzau A; Risaliti A
    Int J Clin Exp Pathol; 2015; 8(10):13304-13. PubMed ID: 26722534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
    Zeng Y; Gao W; Chen X; Shen K
    Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
    Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
    Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
    Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of growth pattern and extension of tumor-associated intraductal carcinoma of the breast.
    Eggemann H; Kalinski T; Ruhland AK; Ignatov T; Costa SD; Ignatov A
    Clin Breast Cancer; 2015 Jun; 15(3):227-33. PubMed ID: 25516401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)?
    Benveniste AP; Ortiz-Perez T; Ebuoma LO; Sepulveda KA; Severs FJ; Roark A; Wang T; Sedgwick EL
    Eur J Radiol; 2017 Nov; 96():74-79. PubMed ID: 29103479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
    Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
    Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions.
    Tsuda H; Hirohashi S
    Pathol Int; 1998 Jul; 48(7):518-25. PubMed ID: 9701014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.